The Efficacy, Onset of Effect, and Safety of Alfuzosin Once Daily in the Treatment of Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia: A Randomized, Placebo-Controlled Trial Using an Acute International Prostate Score
The Efficacy, Onset of Effect, and Safety of Alfuzosin Once Daily in the Treatment of Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia: A Randomized, Placebo-Controlled Trial Using an Acute International Prostate Score
Primary: Evaluate the safety and onset of symptom relief using an acute I-PSS form (7 day
 form).

 Determine onset of urinary peak flow improvement after 7 days Secondary: Determine
 improvement in Bother Score after 7 & 28 days; improvement in sexual function after 28 days;
 assess one-month efficacy and safety
Inclusion Criteria:

 - Men aged greater than or equal to 50 years with a history of lower urinary tract symptoms
 (LUTS) related to BPH for greater than or equal to 6 months, an International Prostate
 Symptom Score (I-PSS) (0 to 35 points scale) of at least 13 points, a maximum urinary flow
 rate (Qmax) between 5 and 12 mL/sec (with a voided volume of greater than or equal to 150
 mL), a residual urine volume of less than or equal to 350 mL, and a bothersomeness score (0
 to 6 points scale) of at least 3 points. All patients will undergo prostate size assessment
 by transrectal ultrasonography (TRUS) if not done within past 12 months.

 Exclusion Criteria:

 - Include, but are not limited to: concomitant lower urinary tract disease; previous
 prostatic surgery; history of postural hypotension or syncope; concomitant use of
 medications that may alter the voiding pattern; and clinically relevant biochemical
 abnormalities. Patients with a serum prostate-specific antigen (PSA) >10 ng/mL will be
 excluded, and those with an elevated serum PSA between 4 and 10 ng/mL must have prostate
 cancer excluded to the satisfaction of the investigator.

 The above information is not intended to contain all considerations relevant to a patient's
 potential participation in a clinical trial.